Multiplexed analysis of polymorphic loci by concurrent interrogation and enzyme-mediated detection

• US 10,415,081 B2
• Filed: 08/04/2016
• Issued: 09/17/2019
• Est. Priority Date: 10/15/2001
• Status: Expired due to Term

• Current Assignee: BioArray Solutions Limited (Werfen SA)
• Original Assignee: BioArray Solutions Limited (Werfen SA)
• Inventors: Li, Alice Xiang, Hashmi, Ghazala, Seul, Michael
• Primary Examiner(s): Priest, Aaron A
• Application Number:
  US15/228,377
• Publication Number:
  US 20160340723A1
• Time in Patent Office: 1,139 Days
• Field of Search: None
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C12Q 1/6827 for detection of mutation or polymorphism
• CPC Class Codes: C12Q 1/6837 using probe arrays or probe chips C12Q1/6874 takes precedence
• CPC Class Codes: C12Q 1/6858 Allele-specific amplification
• CPC Class Codes: C12Q 1/6883 for diseases caused by alterations of genetic material
• CPC Class Codes: C12Q 2527/107 Temperature of melting, i.e. Tm
• CPC Class Codes: C12Q 2535/125 Allele specific primer extension
• CPC Class Codes: C12Q 2565/537 characterised by the capture oligonucleotide acting as a primer
• CPC Class Codes: C12Q 2600/156 Polymorphic or mutational markers
• CPC Class Codes: C12Q 2600/16 Primer sets for multiplex assays

Abstract

The invention provides methods and processes for the identification of polymorphisms at one ore more designated sites, without interference from non-designated sites located within proximity of such designated sites. Probes are provided capable of interrogation of such designated sites in order to determine the composition of each such designated site. By the methods of this invention, one ore more mutations within the CFTR gene and the HLA gene complex can be identified.

Claims

1. A method of concurrent determination of nucleotide composition at designated polymorphic sites located within one or more target nucleotide sequences, said method comprising the following steps:

a. Providing one or more sets of probes, wherein each set of probes comprises two or more member probes,

wherein each of the two or more member probes comprises a terminal elongation initiation (TEI) region and a duplex anchoring (DA) region, wherein the TEI region and the DA region are linked by a neutral linker, wherein the TEI region and the DA region align with separate regions of a target nucleic acid sequence and the neutral linker does not align with the target nucleic acid sequence, and

wherein the TEI region aligns with a subsequence of a target nucleic acid sequence comprising a first designated polymorphic site;

wherein the TEI region comprises each of the two or more member probes'"'"' three or four 3′

terminal nucleotide positions and an interrogation site at its 3′

-most terminal nucleotide position, wherein the interrogation site is perfectly complementary to the first designated polymorphic site, and

wherein the two or more member probes differ in sequence in the TEI region in at least the interrogation site;

wherein the difference in sequence in the TEI region in at least the interrogation site results in each set of probes comprising the two or more member probes required for perfect complementarity to variations in nucleotide sequence at the first polymorphic site; and

wherein each of the two or more member probes is immobilized on an encoded microparticle, said encoded microparticle comprising a distinguishable characteristic that uniquely identifies its immobilized probe;

b. Contacting the one or more sets of probes with one or more target nucleotide sequences in a single multiplexed reaction so as to permit formation of hybridization complexes by placing each of the two or more member probes'"'"' interrogation site in direct alignment with the first designated polymorphic site, wherein the TEI region initiates an elongation reaction to form an elongation product when sequence of the TEI region is complementary to its corresponding subsequence of the target nucleotide at the first designated polymorphic site;

c. Subjecting the hybridization complexes to a polymerase-catalyzed elongation reaction, wherein for each hybridization complex, formation of the elongation product indicates a match or absence of the elongation product indicates a mismatch between the interrogation site and the first designated polymorphic site, and formation of the elongation product results in a change in the distinguishable characteristic; and

d. Determining a change in the distinguishable characteristic for each encoded microparticle to determine the composition of the first designated polymorphic site.

2. The method of claim 1, wherein the polymerase-catalyzed elongation reaction comprises adding one or more deoxynucleotide triphosphates and a polymerase capable of extending or elongating probes, wherein the polymerase lacks 3′

to 5′

exonuclease activity.

3. The method of claim 2, wherein at least one of the deoxynucleotide triphosphates is labeled so as to generate an optically detectable signature associated with the elongation product.

4. The method of claim 1, wherein the one or more target nucleotide sequences are products of at least one polymerase chain reaction.

5. The method of claim 1, wherein the microparticles are encoded by staining with a fluorophore dye.

6. The method of claim 1, wherein the microparticles are encoded by staining with a chromophore dye.

7. The method of claim 1, wherein the microparticles are immobilized on a solid support.

8. The method of claim 1, further comprising determination of a second polymorphic site, wherein the first polymorphic site and the second polymorphic site are correlated, wherein the second polymorphic site is determined by:

contacting the elongation product formed at (c) with a second probe designed to hybridize to the second polymorphic site;

determining hybridization of the second probe to the second designated polymorphic site for each elongation product; and

determining composition of the second designated polymorphic site.

9. The method of claim 1, wherein the subsequence of the target nucleic acid further comprises a non-designated polymorphic site, wherein the two or more member probes further differ in sequence in the TEI region at nucleotide position corresponding to a non-designated polymorphic site, and wherein each set of probes comprises the two or more member probes required for perfect complementarity to each nucleotide sequence combination at the non-designated site and the first polymorphic site.

10. The method of claim 1, wherein the one or more deoxynucleotide triphosphates are not labeled.

11. The method of claim 1, wherein the step of determining is performed in solution.

12. The method of claim 11, wherein the step of determining is performed by flow cytometry.

13. The method of claim 7, wherein the encoded microparticles are randomly immobilized on the solid support.